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Systems biologyIncreases in throughput and decreases in costs have facilitated large scale metabolomics studies, the simulta-
neousmeasurement of large numbers of biochemical components in biological samples. Initial large scale studies
focused on biomarker discovery for disease or disease progression and helped to understand biochemical
pathways underlying disease. The ﬁrst population-based studies that combined metabolomics and genome
wide association studies (mGWAS) have increased our understanding of the (genetic) regulation of biochemical
conversions. Measurements ofmetabolites as intermediate phenotypes are a potentially very powerful approach
to uncover how genetic variation affects disease susceptibility and progression. However, we still face many
hurdles in the interpretation of mGWAS data. Due to the composite nature of many metabolites, single enzymes
may affect the levels ofmultiplemetabolites and, conversely, levels of singlemetabolitesmay be affected bymul-
tiple enzymes. Here, we will provide a global review of the current status ofmGWAS.Wewill speciﬁcally discuss
the application of prior biological knowledge present in databases to the interpretation of mGWAS results and
discuss the potential of mathematical models. As the technology continuously improves to detect metabolites
and to measure genetic variation, it is clear that comprehensive systems biology based approaches are required
to further our insight in the association between genes, metabolites and disease. This article is part of a Special
Issue entitled: From Genome to Function.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
The “inborn errors of metabolism” as deﬁned by Garrod at the
beginning of the twentieth century depict the ﬁrst clearly recognized
examples of speciﬁc genetic defects leading to the accumulation of me-
tabolites in body ﬂuids [1]. For example, in alkaptonuria, a genetic defect
in the enzyme homogentisate 1,2-dioxygenase leads to the accumula-
tion of homogentisic acid and its oxide alkapton in plasma and urine.
Detection of alkapton in urine is relatively simple in that exposure of
urine from affected patients to air results in black discoloration that isciation study;MAF,minor allele
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etics, Leiden University Medical
).readily detected by eye. Alkaptonuria is transmitted as a recessive
Mendelian trait with near complete penetrance and is an example of a
rare metabolic disease caused by rare genetic variants [2].
Changes in plasma metabolites are also pathogenic hallmarks of
common metabolic diseases such as type-2 diabetes. The deﬁning
metabolic marker for type 2 diabetes is glucose, but hyperglycemia co-
occurs with changes in a variety of additional metabolites including
amino acids, lipids and lipoproteins. The high heritability of type 2
diabetes is not explained by rare genetic variants segregating in families,
but is thought to be caused by a variety of, and presumably combination
of common genetic variants. This paradigm is referred to as “common
disease–common variant” hypothesis and is pursued in so-called
genome wide association studies (GWAS). In GWAS, genome wide
genotyping platforms measure genotypes for hundred thousand to
millions of single nucleotide polymorphisms (SNPs) with minor allele
frequencies (MAF) generally larger than 0.05 and test each of those
SNPs for association with a speciﬁc trait [3]. A large number of GWAS
have been performed with a variety of both binary traits (e.g. type 2 di-
abetes) and quantitative traits (e.g. fasting glucose levels). These studies
have successfully uncovered genetic variants that contribute to disease
risk and also to the variation in quantitative phenotypes [4]. For
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identiﬁed, giving novel insights into the complex pathophysiology of
the disease. However, the risk attributed to individual SNPs in the vicin-
ity of even the strongest candidate gene, transcription factor 7-like 2
(TCF7L2), is relatively modest (odds ratios of 1.5–1.7) [5]. Moreover,
the combined genetic loci discovered to date explain only a small pro-
portion (less than 5%) of the observed heritability of type 2 diabetes.
Thus, a signiﬁcant proportion of the observed heritability remains to
be uncovered [6].
Since a large proportion of the SNPs discovered through GWAS are
intergenic or lie within the intronic regions of genes, rather than in
the protein coding sequences, the genetic basis for the association is
often not obvious. It is possible that the SNPs discovered through
GWAS are in linkage disequilibrium (LD) with the real causal variant
that is not captured by the platform. This hypothesis to uncover
“missing heritability” is currently being tested by many labs using
next generation deep sequencing approaches to screen the whole ge-
nome or whole exome to locate the functional variants. Unfortunately,
thus far, these approaches have met with relatively limited success.
This lack of success may be associated with our inability to recognize
the causative variants among themany detected variants. Alternatively,
GWAS hits may constitute expression quantitative trait loci (eQTLs)
inﬂuencing the expression level of one or more genes nearby (cis-
eQTLs), or at a distant physical location (trans-eQTLs) [7,8]. Recently, a
combination of RNA and genome sequencing has provided in-depth
insight into the relation between genetic variation and transcriptome
variation and their association with functional variation [9].
Whereas it is often difﬁcult to determine the effect of GWAS-
discovered SNPs on nearby or distant genes, it is clear that many differ-
ent genes and loci are involved in the pathogenesis of complex diseases
such as type 2 diabetes. In addition, it is also clear that environmental
factors including lifestyle (i.e. diet and physical activity) affect the
development of diabetes. Therefore, it may be more appropriate to con-
sider commonmetabolic disorders such as diabetes as the outcome of a
variety and often combination of mild “inborn errors of metabolism” in
conjunction with the environment. These mild “inborn errors of
metabolism” would be reﬂected by differences in the concentrations
of metabolites in cells and/or body ﬂuids and could provide insight
into the “missing heritability”. The terms “genetically determined
metabotype” (GDM) [10] and “genetically inﬂuenced metabotype”
(GIM) have been coined for this [11]. GIM has been deﬁned as relatively
prevalent genetic variants that lead to substantial modiﬁcation in the
efﬁciency of metabolic conversions [12]. The combination of GIMs in
any given individual determines his metabolic individuality and thus,
in combination with environment and lifestyle, the risk for metabolic
disorders such as type 2 diabetes.
2. Metabolomics measurements
The detection of GIMs has been facilitated by technological develop-
ments in the ﬁeld of metabolomics, where it is now possible to simulta-
neously measure hundreds of metabolites in large sets of biological
samples using automated procedures, and at relatively low cost
(10s of euros per sample). A variety of metabolomics platforms are
available, all having their own characteristics. Generally speaking, the
metabolomics techniques can be divided in two types of platforms
and two types of approaches. Metabolomics platforms based on mass
spectrometry (MS) in general require extensive sample preparation
and are used in-line with gas or liquid chromatography (GC-MS and
LC-MS). In contrast, nuclear magnetic resonance (NMR) based plat-
forms require relatively limited sample preparation and the samples
can be analyzed without prior separation procedures. MS and NMR
based platforms can be employed for targeted and/or non-targeted
approaches. In a targeted approach, the platform is optimized for
detection of a set of predeﬁnedmetabolites and absolute or relative con-
centrations are determined using internal standards. In contrast, in anon-targeted approach, the platform is optimized to capture global
snapshots of the test and reference samples and reports the differences.
To subsequently identify the metabolites underlying the differential
signal in the untargeted approach, additional analyses are required
that are frequently challenging. Therefore, metabolomics datasets
from a non-targeted approach often contain a large number of
‘unknown’ compounds. The main characteristic of all metabolomics
platforms is that a subset of compounds can be detected based on com-
mon chemical properties of these compounds rather than their biologi-
cal relatedness. No single analytical technique exists that is suitable for
the identiﬁcation and quantiﬁcation of all endogenous metabolites in
a sample.
Excellent reviews on the possibilities and challenges of the different
metabolomics platforms and approaches are available [13–15]. In
general, NMR spectroscopy is highly reproducible and quantitative.
However, NMR spectroscopy is relatively insensitive and metabolite
identiﬁcation relies on specialized and mostly proprietary spectral
deconvolution algorithms. These algorithms may not always identify
the same metabolites and may not always base the identiﬁcation of a
speciﬁc metabolite on the same spectral signal. In contrast, MS based
platforms provide highly precise information on metabolite mass from
which identity can often be inferred. However, metabolite quantiﬁca-
tion requires spiked internal standards. Thus, a common challenge in
metabolomics on any platform is the reproducibility of reportedmetab-
olite levels across different laboratories. In addition to these platform-
speciﬁc challenges, additional variability may be caused by differences
in instrumentation and experimental setup conditions such as sample
preparation and extractionmethod, collection protocols, sourcemateri-
al (plasma, serum, urine, etc.), but also sample storage conditions and
batch effects. These aspects all require careful consideration when rep-
licating observations and poolingmetabolomics data for meta-analyses.
3. Genome wide association studies of metabolomics data
Since metabolomics data are (semi)quantitative, they are suited for
metabolomics GWAS (mGWAS), uncovering genetic variants that affect
metabolite levels. One of the ﬁrst studies employed an MS-based
platform that could identify and quantify up to 363 metabolites in 284
individuals [10]. The study reported that common SNPs explained up
to 12% of the observed variance in metabolite levels. Moreover, the
study determined that the explained variance could be dramatically in-
creased by considering ratios of metabolites. This is because analyzing
ratios of metabolite concentrations potentially reduces the variation in
the dataset when the pair of metabolites is related to the substrate
and product of a given enzymatic reaction. Furthermore, where a SNP
impacts such ametabolic reaction, consideration of ratios leads to a dra-
matic reduction in the p-value of association. For example, rs174548, a
SNP in an intron of the fatty acid delta-5 desaturase 1 (FADS1) gene is
associated with a phosphatidylcholine moiety, PC C36:4 (36 denotes
the number of carbons in the side chains and 4 denotes the number of
double bonds) levels with a p-value of 4.52 × 10−8, slightly above the
genome-wide threshold. However, association of the same SNP with
the ratio of PC C36:4/PC C36:3 has a p-value of 2.4 × 10−22, a reduction
by 14 orders of magnitude. The FADS1 enzyme introduces a double
bond in long chain polyunsaturated fatty acids and the moieties PC
C36:3 and PC C36:4 are related to the substrate and product of this en-
zymatic reaction.
A consistent theme that has emerged from mGWAS is that signiﬁ-
cant SNP–metabolite associations point to the underlying biological
mechanism. This is in contrast to GWAS of clinical endpoints where
unravelling the underlyingmechanism is oftenmuchmore challenging.
In addition to FADS1, several other associations have shown that the
functional nature of the genematcheswith the biochemical characteris-
tics of the associated metabolite. For example, SNPs in the gene GLS2
(glutamine synthase 2) have been found associated with glutamine
[16,17].This is a biologically plausible association because the enzyme
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hits with unknown gene function offer an opportunity to infer novel bi-
ological mechanism underlying the SNP–metabolite association. For ex-
ample, as a proof of principle, Suhre et al. experimentally investigated
the association of the SNP rs7094971 in the solute carrier family 16,
member 9 (SLC16A9) with carnitine. The study validated that the
hitherto uncharacterized protein was indeed a carnitine transporter in
Xenopus oocytes [17]. This result underscores the utility of mGWAS in
uncovering novel functions and identifying candidate genes for further
study.
Table 1 provides an overview of published mGWAS, their character-
istics and main ﬁndings. It is obvious that the number of highly signiﬁ-
cant associations is overwhelming and that many of these associations
have yet to be interpreted in their proper pathophysiological context.
The heritability of small metabolites and amino acids has been reported
to vary between 23% and 55%. The heritability of lipids and lipoproteins
is somewhat higher ranging, respectively, from 48% to 62% and 50% to
76% [16]. A recent report from a community based cohort indicates
that for the majority of metabolites, heritability explains N20% of
inter-individual variation and that variation attributable to heritable
factors is greater than that attributable to clinical factors [18]. The
non-heritable proportion of the variation in metabolite levels is likely
due to factors such as age, gender, menopause, medication, smoking,
nutrition and underlying diseases. The relative contribution and inter-
play of each of these factors require larger mGWAS and modeling of
gene × environment interactions.
4. Challenges associated with mGWAS
Metabolomics platforms generally yield information on the levels of
one to several hundreds of metabolites. Consideration of all metabolites
results in a severemultiple testing burden. This precludes genuine SNP–
metabolite pairs from being considered when they fail to reach the
stringent statistical threshold for signiﬁcance. This problem is further
exacerbated when consideringmetabolite ratios. The p-value threshold
for a single outcome GWAS is determined by the number of indepen-
dent genomic loci. Due to the intricate LD structure of the human
genome, this p-value is typically set at p b 5 × 10−8. Similar to SNPs in
LD, a signiﬁcant proportion of the metabolites are highly correlated to
other often similar metabolites and cannot be considered as indepen-
dent. To account formultiple test correction, some groups have comput-
ed the Bonferroni correction by counting all the metabolites [10,17,19],
while a few other groups have adopted a less stringent strategy by tak-
ing into account the number of independentmetabolites as determined
by a principle component analysis [20]. A standardized approach to deal
with the multiple testing issue in mGWAS remains to be formulated.
Another issue relates to the reporting of novel hits. In conventional
GWAS, a hit for a speciﬁc phenotype is novel if it is independent from
previously reported SNPs that are associated with the phenotype. In
mGWAS, some of the hits associate with closely related yet non-
identical metabolites/phenotypes. In these cases, the association but
not the SNP is novel.
The mGWAS that have been reported so far followed the classical
GWAS approach to uncover genetic variants affecting metabolites and
metabolite ratios. The selection of metabolite ratios for GWAS has
been done based on selected prior knowledge or simply by analyzing
all possible combinations. For example, Illig et al. analyzed the whole
ratio matrix of 163 metabolites quantiﬁed by a commercial targeted
array designed to capture a selection of sugars, amino-acids, acyl-
carnitines and phospholipids. Despite the burden of multiple testing in-
herent to this approach, they still were able to capture associations
below the signiﬁcance threshold, particularly for the FADS locus [19].
This is likely due to the fact that both the substrate and the product of
the FADS enzymes were present in the platform, which may not be al-
ways the case for other metabolites and enzymes. Our group followed
a similar approach and performed an mGWAS for phospholipids andsphingolipids. To decrease the burden of multiple testing we used the
proportion of each metabolite within its own class, in addition to its
absolute concentration and reported additional 6 new loci for these
molecules [20]. However, these unbiased but naive approaches seem
insufﬁcient to fully exploit the data generated by the metabolomics
platforms. Although increasing the sample size will reveal novel genes
affecting metabolite levels, additional novel approaches that utilize
knowledge of biological relatedness between the molecules are
required to take mGWAS one step further.
Various genes that have been identiﬁed thus far to affect metabolite
levels have also been identiﬁed in GWAS of conventional metabolic
traits, such as glucose and total plasma lipids. For example, variation
in the FADS gene cluster is associated with the fatty acid composition
of phospholipids, but also fasting glucose levels, triglycerides and total
cholesterol (Table 1 and [21]). In addition, the FADS gene cluster has
also been associated with the intermediary outcome intima media
thickness [20]. These data are in agreement with the notion that phos-
pholipids are somehowcausally involved in oneof theﬁrst steps leading
to disturbances in glucose and/or lipid metabolism and subsequent
cardio-metabolic disease. However, numerous hypotheses can be
formulated to link phospholipids with cardio-metabolic disease. These
hypotheses include changes in cellular membrane properties and thus
receptor function, but also changes in lipoprotein surface properties
and function. Whether any or all of these potential mechanisms play a
role in the link between the FADS gene cluster and disease remains to
be determined and experimentally validated. However, detailed insight
into the speciﬁc pathways that are affected by variation in phospho-
lipids is a required ﬁrst step to select the most likely hypotheses.
5. Pathway analysis of mGWAS data
Pathway analysis is exquisitely suited to increase the statistical
power to identify biologically plausible loci and simultaneously improve
our understanding of the underlying biological mechanisms. Pathway-
based approaches examine test statistics for a group of genes in contrast
to single-marker analysis. The ‘group of genes’ is an expert deﬁned set
that is functionally related to the phenotype. The utility of this tech-
nique to identify novel and biologically meaningful loci has already
been shown in GWAS with clinical endpoints [22–25]. Furthermore,
pathway based approaches are uniquely suited to mGWAS owing to
the abundance of knowledge on proteins involved inmetabolite conver-
sion and secretion, as captured in various databases of metabolic
pathways and reactions.
The term ‘pathway’ in a pathway analysis is usually referring to a set
of functionally related genes participating in a common biological
process. The resources of prior knowledge that are commonly used in
pathway analysis include controlled vocabularies like Gene Ontology
[26], manually curated gene sets from MSigDB [27] and the pathway
databases like KEGG[28], BioCyc[29] and REACTOME [30]. Metabolic
pathways offer the ideal knowledge resource for pathway analysis in
mGWAS due to the direct relationship between entities represented in
these databases and compounds measured onmetabolomics platforms.
Metabolic pathways consist of three tiers of information: 1) metabo-
lites at the lowest level; 2) reactions built from metabolites and the
enzymes that drive these reactions; and 3) pathways built upon
reactions [31]. Pathway databases like KEGG, BioCyc and Reactome
have extended our knowledge of human metabolism. However, no
single database captures all relevant biochemical knowledge and
conceptual differences between the databases pose a serious challenge
to knowledge integration efforts [31,32]. For example, a study [33]
published in 2011 found that the consensus among ﬁve major pathway
databases at the level of the genes is 13%, at the level of enzyme commis-
sion (EC) numbers is 18%, at the level ofmetabolites is 9% and at the level
of the reactions ismerely 3%. The lack of consensus inmetabolite speciﬁc
databases extends to resources like HMDB [34] and ChEBI [35] due to dif-
fering representation of common metabolites and reactions. Three
Table 1
Overview of published mGWAS datasets. Characteristic features of the study are shown in the table. PC: phosphatidylcholine, SM: sphingomyelin, PE: phosphatidylethanolamine, HDL: high-density lipoprotein, LDL: low-density-lipoprotein, VLDL:
very-low-density-lipoprotein, TG: triglycerides, PL: phospholipid, LPC: lysophosphatidylcholine, TC: total cholesterol, PUFA: polyunsaturated fatty acid, Fischer's ratio: (valine + leucine + isoleucine)/(phenylalanine + tyrosine), uk: unknown
(not-assigned) peak. *not deﬁned, **reported by two different study groups at the same time.
Study Platform Metabolites MAF Genotypes Sample Discovery Replication Novel hits Known hits Correction M-GWAS
P-VALUE
[10] Gieger,
2008
ESI-MS/MS Metabolites and
ratios (n = 363)
N0.05 Affy GeneChip
Human Mapping
500 K
Serum KORAF3 (n = 284) None Reported suggestively signiﬁcant:
PC-FADS1, SM-FADS1, PE-LIPC, SM-LIPC,
SM-PLEK, lysine-PARK2, SM-ANKRD30A,
propionylcarnitine/butyrylcarnitine-SCAD,
lauroylcarnitine/octanoylcarnitine-MCAD
None Bonferroni 1.33 × 10−9
[69] Tanaka,
2008
GC n-3 and n-6 fatty
acids (n = 6)
* Illumina Inﬁnium
HumanHap550
Plasma InCHIANTI
(n = 1075)
GOLDN
(n = 1076)
None FADS1 and ELOVL2 None 1.0 × 10−7
[70] Hicks,
2009
ESI-MS/MS Sphingolipids and
proportions
(n = 76)
* Illumina Inﬁnium
HumanHap300
Plasma,
Serum
EUROSPAN
(n = 4110)
None Ceramide-ATP10D, SM-SGPP1, SM-LASS4,
ceramide-LASS4, ceramide-SPTLC3
SM-FADS1 Bonferroni
(n = 76)
1.0 × 10−10
[71] Chasman,
2009
1H-NMR
(LipoProtein-I
and II assays)
and direct assay
Lipoproteins
(n = 22)
N0.01 HumanHap300
Duo chips
Plasma WGHS
(n = 17296)
PROCARDIS
(n = 200), FHS
(n = 2700)
Small HDL-PCCB, TG-BTNL2, medium
VLDL-PPP1R3B, small LDL-KLF14, total
HDL-PAH, large HDL-DNAH10, medium
HDL-WIPI1
apoB-PCSK9, VLDL-ANGPTL3,
apoB-CELSR2/PSRC1/SPRT1, medium
HDL-APOA2, small VLDL-APOB,
TG-GCKR, LDL cholesterol-ABCG5,
HDL cholesterol-COBLL1/GRB14, LDL
cholesterol-HMGCR, TG-BTNL2,
TG-MLXIPL, medium VLDL-PPP1R3B,
medium VLDL-LPL, small LDL-TRIB1,
apoA1-ABCA1, small VLDL-ABO, large
HDL-FADS1-3, medium VLDL-APOA1-5,
LDL cholesterol-HNF1A, large HDL-LIPC,
large HDL-CETP, apoA1-LIPG, LDL
cholesterol-LDLR, total LDL-APOC1-
APOE, apoA1-HNF4A, small HDL-PLTP
None 5.0 × 10−8
[19] Illig, 2010 Biocrates Metabolites
(n = 163) and
ratios
N0.1 Affymetrix 6.0
GeneChip and
Illumina Hap317K
Serum KORAF4
(n = 1029)
KORA F4
(n = 780),
female TWINSUK
(422)-3 step
design
Reported suggestive loci: glycine/PC-CPS1,
valine/Isovalerylcarnitine-SLC22A4, PC
and PC ratios-SYNE2(SGPP1) and
signiﬁcant loci: PC and PC ratios-FADS1,
PC and PC ratios-ELOVL2, carnitine ratios-
SCAD(ACADS), carnitine ratios-
MCAD(ACADM), carnitine ratios-
ACADL(LCAD), PC and PC ratios PLEKHH1,
SM and SM ratios-SPTLC3, carnitine
ratios-ETFHD, carnitine-SLC16A9
None Bonferroni* 3.64 × 10−12
[17] Suhre,
2011
Metabolon
(UHPLC/MS/
MS2 and
GC-MS)
N250 metabolites
and ratios yielding
(n = 37,000)
N0.01 Affymetrix 6.0
GeneChip
(discovery),
HumanHap300,
HumanHap610Q,
1 M-Duo and 1.2MDuo
1 M(replication)
followed by HapMap2
imputations
Serum KORAF4
(n = 1768)
TWINSUK
(N = 1052)
5-Oxoproline-OPLAH, myristate/
myritsoleate-SCD, androsterone sulphate-
CYP3A4, 10-nonadeceonate/
10-undeceonate-CYP4A, glycine-CPS1,
succinylcarnitine-LACTB,
isobutyrlcarnitine-SLC22A1, serine-PHGDH,
ﬁbrinogen cleavage peptide ratio-ENPEP,
andosterone sulphate/epiandrosterone
sulphate-AKR1C, inosine-NT5E, proline-
PRODH, alpha-hydroxyisovalerate-HPS5,
ﬁbrinogen cleavage peptine ratio-ALPL,
bradykinin-KLKB1, glutamine-GLS2,
caffeine/quinate-AHR, lactate/
isovelarylcarnitine-IVD, decanoylcarnitine-
ETFDH, glutaorylcarnitine/lysine-SLC7A9,
docosahexaenoic acid/eicosapentaenoic
acid-ELOVL2, carnitine-SLC16A9, isoleucine/
tyrosine-SLC16A10
Butyrylcarnitine/propinylcarnitine-
ACADS, N-acetylornithine-NAT8, PC
and PC ratios-FADS1, bilirubin/
oleolylcarnitine-UGT1A,
hexaonlycarnitine/oleate-ACADM,
glucose/mannose-GCKR,
methylxanthine/4-
acetamidobutanoate-NAT2, ﬁbrinogen
cleavage peptide ratio-ABO, urate-
SLC2A9, eicosenoate/
tetradecanedionate-SLC01B1, ﬁbrinogen
cleavage peptide ratio-FUT2, aspartyl-
phenyalanine-ACE, isovalerylcarnitine-
SLC22A4, LPC and LPC ratios-PDXDC1
Bonferroni
(n = 37,000)
2.0 × 10−12
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[72]Nicholson,
2011
1H-NMR and
Biocrates
(FIA-MS)
526 redundant
NMR peaks and
Biocrates
metabolites
(n = 163)
N0.01 HapMap 2 Plasma,
urine
MolTWIN
(n = 142)
females,
longitudinal
MolOBB
(n = 69)
Trimethylamine-PYROXD2,
dimethylamine-PYROXD2, N-acetylated
compound-NAT8
3-Aminoisobutyrate-AGXT2**
[73] Suhre,
2011
1H-NMR
followed by
CHENOMX
NMR suit 6.1
56 metabolites
and 1661 ratios
* Affymetrix Human
SNP array 6.0
Urine SHIP (males,
n = 862)
SHIP(n = 1032),
Longitudinal
sample(n = 170),
KORAF4
(n = 992)
Formate/succinate-NAT2, lysine/valine-
SLC7A9
3-Aminoisobutyrate-AGXT2**,
2-hydroxyisobutyrate-WDR66,
alanine/dimethylglycine-SLC6A20
Bonferroni
(n = 1720)
4.51 × 10−11
[74] Lemaitre
2011
GC n-3 fatty acids
(n = 4)
N0.01 HapMap 2 Plasma CHARGE
(n = 8866)
None Docosapentanoic acid-GCKR Alpha-linolenic acid-FADS1-2,
eicosapentaenoic acid-FADS1-2,
docosapentanoic acid-FADS1-2,
eicosapentaenoic acid,
docosapentanoic acid,
docosahexaenoic acid-ELOVL2
None 5.0 × 10−8
[20] Demirkan,
2012
ESI-MS/MS Sphingolipids,
Phospholipids,
(n = 115) and
their proportions
None HapMap 2 Plasma,
serum
EUROSPAN
(n = 4034)
None PE-PAQR9, PC-AGPAT1, LPC-PKD2L1,
SM-PLD2, SM-APOE
PC-GCKR, PC-ELOVL2, PC-FADS1-2,
PC-APOA5, PC-PLEKHH1, PE-LIPC,
ceramide-ATP10D, SM-SGPP1, SM-
LASS4, SM-SPTLC3, LPC-PDXDC1
Bonferroni
(n = 23
independent
vectors)
2.2 × 10−9
[16] Kettunen,
2012
1H-NMR, LIPO
and LMWM
extraction
windows
Lipoproteins,
lipids, small
metabolites
(n = 117) and
99 selected ratios.
* 7.7 M imputed SNPs
from a custom made
reference set of
HapMap 3 and
1000G
Serum NFBC1966,
YF, HBCS,
GenMets,
DILGOM, Twins
(n = 8330)
None Alanine/valine-SLC1A4, Fischer's ratio-
PPM1K, phenylalanine-F12, glutamine/
histidine-DHDPSL, phenylalanine/
tyrosine-TAT, Fischer's ratio-SLC2A4,
citrate-SLC25A1, x-large HDL-FCGR2B,
albumin-ALB, xx-large VLDL-PPP1R11,
linoleic acid/PUFA-CPT1A.
Alanine/glutamine-GCKR, glucose-
G6PC2, histidine/valine-KLKB1,
alanine/tyrosine-SLC16A10, glucose-
MTNR1B, glutamine/glucose-GLS2,
large LDL free cholesterol-PCSK9,
mobile lipids-ANGPTL3, VLDL
diameter-MLXIPL, medium VLDL
PL-LPL, TC/esteriﬁed cholesterol-
ABCA1, linoleic acid/PUFA-FADS1,
valine/TG-APOA1, x-large HDL TG-LPL,
linoleic acid/PUFA-PDXDC1, HDL
cholesterol-CETP, x-large HDL TG-LIPG,
medium LDL cholesterol/medium
LDL PL-LDLR, large LDL free
cholesterol-APOE, large HDL lipid
content/medium HDL lipid
content-PLTP
Bonferroni
(n = 216)
2.31 × 10−10
[75] Wu, 2013 GC Fatty acids
(n = 4)
N0.01 HapMap 2 Plasma CHARGE
Consortium
(n = 8961)
None Palmitic acid, stearic acid-ALG14,
palmitoleic acid, oleic acid and stearic
acid-FADS1, stearic acid-LPAGT1,
palmitoleic acid-GCKR, palmitoleic
acid -PKD2L1 and a locus on
chromosome 2.
None None 5.0 × 10−8
[76] Rueedi,
2014
1H-NMR Redundant
NMR features
(n = 1276)
* HapMap 2
(discovery)
Illumina OmniQuad
(replication)
Urine Colaus
(n = 835)
TasteSensomics
(n = 601)
uk-PYROXD2, fucose-FUT N-acetylated compounds-
ALMS1(NAT8), uk-ACADL,
3-aminoisobutyrate-AGXT2, uk-NAT2,
uk-ABO, trimethylamine-PYROXD2,
uk-PYROXD2, uk-ACADS,
2-hydroxyisobutyrate-PSDM9,
lysine-SLC7A9
Bonferroni
(n = 125)
5.7 × 10−10
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tempt to automate the reconciliation of metabolite and reaction
information.
Pathway analysis entails selecting a pre-deﬁned set of genes or
pathways to test for enrichment. This selection is generally based on
the relevance of the test set to the phenotype being assessed by the
GWAS. The generation of gene sets relevant to metabolites requires a
systematic interrogation of metabolite databases and depends heavily
on the accessibility and download formats made available by the data-
base. Furthermore, it is important that the software developed to gener-
ate such gene sets is easy to use. To address these issues, we have
developed tools to systematically interrogate on-line databases using
Taverna [38], a workﬂow-based management system. Taverna allows
users access to remote data resources like KEGG, BioCyc, Ensembl [39]
and NCBI [http://www.ncbi.nlm.nih.gov/] and data management
systems like Biomart [40] through implementation of web services. To
generate a gene set for each of the metabolites measured on a metabo-
lomics platform, we designed workﬂows to interrogate pathway data-
bases and retrieve genes from pathways and reactions relevant to the
metabolite [41]. A corresponding SNP set (SNPs present in ±25 kb
ﬂanking region of the genes) was generated for each of themetabolites.
As a proof of principle, we investigated the utility of the reduced and bi-
ologically relevant SNP set to identify known and novel association from
a published GWAdataset by Illig et al. [19]. The smaller SNP set reduced
themultiple-testing threshold by around two orders of magnitude. This
reduction helped us discover novel SNP–metabolite associations in the
Illig et al. GWAS datasets [41]. For example, a SNP in the gene
ALDH1L1 (aldehyde dehydrogenase 1 L1) was found associated with
the ratio of serine/glycine. The original studymissed this association be-
cause the p-value cut-off in the discovery stage of the study precluded
this association from being considered in the replication stage.
ALDH1L1 is an important component of the one-carbon pool pathway
and acts upstream of SHMT (serine hydroxy methyl transferase) en-
zyme that mediates the bulk of glycine to serine conversion in the cell.
This reafﬁrms the notion that a method that relies on background
knowledge present in pathway databases has the ability to reduce the
multiple test burden and thereby facilitate the discovery of true
positives in GWAS results. It should be noted that assignment of SNPs
to genes represents a challenge in itself. It is common to include only
SNPs in the coding region of the gene or within a certain, more or less
arbitrary, distance threshold. However, Hong et al. [42] note that the re-
liable conversion of SNPs to representative genes is not trivial and that
positional gene clustering if not corrected for can lead to spurious re-
sults in a pathway analysis. Properly accounting for LD structure and
knowledge on eQTLs will help to link SNPs to the right genes.
Our pathway analysis approach to alleviate themultiple-testing bur-
den through selective testing of SNPs can be seen as complementary to
conventional GWAS analysis. However, pathway analysis can also be
used in a post-GWAS setting to identify enriched pathways within the
identiﬁed signiﬁcantly associated SNPs. We have reported [20] a
pathway analysis designed to identify enriched pathways using web
accessible softwaremade available by ConsensusPathDB [43]. The latter
is a database that integrates pathways and interaction resources made
available by databases like KEGG, BioCyc and Reactome. The study re-
ported the enrichment of the following pathways for phospholipid
traits: glycerolipid metabolism, chylomicron-mediated lipid transport,
triglyceride biosynthesis and metabolism of lipids and lipoproteins.
The list of enriched pathways functionally matches the traits, thus rein-
forcing the importance of pathway analysis in such studies.
Pathway analysis approaches for GWAS can be categorized based on
the type of input data and the speciﬁc null hypothesis that is being test-
ed [44]. With regard to input data, there are two types of approaches;
one approach uses SNP p-values and the other approach uses the effect
sizes derived from SNP phenotype data (beta's) to calculate pathway-
level statistics. With regard to the null hypothesis being tested, two
approaches are available: competitive tests and self-contained tests. Acompetitive test compares the test statistic of a gene set to a standard
deﬁned by its complement. In contrast, a self-contained test compares
the test statistic of the gene set to a ﬁxed standard and does not take
into account genes in other gene sets. The issues and solutions to SNP-
to-gene mapping and tests for gene set enrichment are common to all
GWAS and we would like to direct the readers to other excellent
reviews [44–46].
6. Gaussian Graphical Modeling
Gaussian Graphical Modelling (GGM) is an unbiased and database
independent approach to reconstruct metabolic networks from large-
scale metabolomics data sets [47]. GGMs are undirected probabilistic
graphical models, in which pairwise correlations between metabolites
are conditioned against the correlations with all other metabolites in
the dataset. Krumsiek et al. [47] demonstrated that the high partial cor-
relations represent direct interactions and that groups of metabolites
that score highly in the correlation matrix can be attributed to reaction
steps in known pathways. As indicated earlier, non-targeted metabolo-
mics platforms also quantify many ‘unknown’ metabolites. This issue
was addressed in a recent work by Krumsiek et al. [48] who demon-
strated that unknown metabolites can be identiﬁed by integrating
GGMs with mGWAS results. Their method exploits partial correlations
between known and unknownmetabolites in addition to their associa-
tion to speciﬁc loci in order to generate a hypothesis regarding the iden-
tity of the unknown metabolites. Through experimental validation the
study provided genetic and biochemical evidence for classiﬁcation of
several unknown metabolites. These studies demonstrate that GGMs
in combination with mGWAS could potentially facilitate metabolite
classiﬁcation and also provide a more comprehensive elucidation of
enzyme-metabolite relationship and metabolic pathways.
7. Pleiotropy in mGWAS
Most metabolomics platforms measure numerous metabolites that
are highly related and correlated to each other. For example, the
Biocrates Absolute IDQ© p150 mass-spectrometry based platform
measures up to 163 metabolites belonging to the classes of amino
acids, carnitines, and phospholipids. Of the phospholipids, 90 different
PCs are measured that only differ based on alkyl/acyl bonds, number
of single/double bonds and length of the side chains. Genes that affect
the levels or degree of saturation of fatty acids also inﬂuence the
phospholipid pool. Hence, several loci that participate in fatty acid
metabolism associate with multiple phosphatidylcholines [10,19,20].
Pleiotropy, the association of a genotype with multiple phenotypes,
represents an opportunity to increase the power to identify novel loci
and gain insight in metabolic pathways. However, GWAS based on uni-
variate statistical analysis does not take pleiotropy into account. A few
groups have developed algorithms and software to exploit the potential
of increased statistical power using multivariate statistical analysis
[49–54]. Ried et al. [49] developed a method called “Phenotype Set
Enrichment Analysis” (PSEA) for the analysis of gene effects on iron-
related and blood count traits. The aim of PSEA is to test if a predeﬁned
set of phenotypes is associated with a gene. The advantage of such a
joint analysis is two-fold: ﬁrst, the combined analysis of multiple
phenotypes can provide insight into the underlying genetic basis and sec-
ond, it leads to improved statistical power in comparison to association
analysis of single phenotypes. PSEA is based on the idea of gene set
enrichment analysis for the investigation of phenotype sets. The analysis
consists of four steps: i) generate a gene-wise test statistic per phenotype;
ii) determine an enrichment score for each combination of phenotype set
and gene; iii) a permutation test to determine the enrichment of a pheno-
type set; and iv) determine the statistical signiﬁcance of the phenotype
set and account for multiple test correction. In another study, Stephens
et al. [50] report a uniﬁed framework that extensively relies on Bayesian
statistics for association analysis of multiple related phenotypes. The
ZNF697 
PHGDH 
HMGCS2 
REG4 
mQTLs
genes
gene set analysis 
metabotype 
network/graph analysis constraint based analysis 
Al
an
in
e,
 
a
sp
ar
ta
te
 
a
n
d 
gl
u
ta
m
at
e
 
m
et
a
bo
lis
m
G
lyc
e
ro
ph
o
sp
ho
lip
id
 
m
e
ta
bo
lis
m
Pe
ro
x
iso
m
e
C
ys
te
in
e
 
a
n
d 
m
et
hi
o
n
in
e
 
m
e
ta
bo
lis
m
Am
in
o
ac
yl
 
tR
N
A 
bi
o
sy
n
th
es
is
G
lyc
in
e,
 
se
rin
e
 
a
n
d 
th
re
o
n
in
e
 
m
e
ta
bo
lis
m
Sp
hi
n
go
lip
id
 
m
e
ta
bo
lis
m
G
lyo
x
yl
at
e
 
an
d 
di
ca
rb
o
xy
la
te
 m
e
ta
bo
lis
m
HMGCL
YARS
HYI
PRDX1
SCP2
PARS2
PPAP2B
CTH
ABCD3
SARS
AHCYL1
CEPT1
WARS2
HAO2
PHGDH
PEX11B
TARS2
CERS2
PMVK
GBA
PEX19
DARS2
GLUL
PLA2G4A
ETNK2
LPGAT1
EPRS
IARS2
DEGS1
GNPAT
Serine 
AKG3-Phosphoserine
3-Phosphonooxypyruvate
Pi
3PG
Glutamate 
Glycerate 
Pi
Pyruvate 
NH3
Alanine 
Hydroxypyruvate
Pi
Box 1. Pathway analysis ofmGWAS results. The ﬁrst step of pathway analysis consists ofmapping the locus associatedwith themetabolite level to a set of candidate genes. Candidate gene
selection may be based on LD, vicinity to the associated locus or the fact that the locus affects the expression of a gene at some distance (eQTL). An alternative approach for selecting can-
didate genes frommGWAS results is to aggregate the p-values of all SNPs that lie close to a gene into a gene-wise p-value and subsequently consider signiﬁcant genes. The next step in-
volves integrating the selected genes with knowledge from pathway databases and/or metabolic models. Three separate approaches can be distinguished at this point: (1) gene set
analysis, (2) network or graph analysis and (3) constraint based analysis. (1) Gene set analysis employs expert derived gene sets representing biological pathways and processes to de-
termine whether certain sets are statistically enriched for the selected genes. (2) Network analysis uses the topology of a biological network to identify enriched submodules. The most
commonly used biological networks are Protein–Protein Interaction (PPI) networks and metabolic networks that consist of graphs with edges between metabolites and enzymatically
catalyzed reactions (represented by squares and circles, respectively, in the diagram). (3) Constraint based analysis (CBA) provides a set of mathematical techniques that characterize
the functional capacity of a metabolic network in terms of the feasible ﬂuxes through the network. In contrast to traditional network analysis, CBA takes into account the steady state
and thermodynamic constraints that are imposed by the set of reactions. That is, internal metabolites may not be net produced or consumed and the ﬂux through irreversible reactions
must be non-negative [57–61]. CBA requires well curated genome scale models such as developed by Thiele et al. [56]. In the diagram the Manhattan plot of a GWAS on serine levels is
shown, focusing on the locus inside the PHGDH gene that was ﬁrst discovered by Sühre et al. [17]. The enzyme encoded by PHGDH catalyzes the conversion of 3-phospho-D-glycerate
(3PG) to 3-phosphonooxypyruvate. Mapping this gene to the pathway gene sets deﬁned in KEGG shows that it occurs in the “glycine, serine and threonine metabolism” pathway
(rn00260), which provides a direct link to serine. Using network analysis, several possible paths are found between the reaction catalyzed by PHGDH and serine that could explain the
association between gene and metabolite. Finally, CBA gives a more speciﬁc result and shows that PHGDH plays a role in serine biosynthesis.
1929H. Dharuri et al. / Biochimica et Biophysica Acta 1842 (2014) 1923–1931
1930 H. Dharuri et al. / Biochimica et Biophysica Acta 1842 (2014) 1923–1931utility of the method is illustrated with an application to a genome-wide
association study of blood lipid traits from the Global Lipids consortium.
To identify novel associations the study applied a two-stage process
where in the ﬁrst stage promising SNPs were identiﬁed by applying
univariate and multivariate tests to every SNP and in the second stage a
Bayesian analysis was performed on the set of promising SNPs. The
method could identify 18 potentially novel genetic associations that
were not identiﬁed by the traditional univariate analysis. In general, how-
ever, a limitation ofmultivariate algorithms is that they operate only for a
modest number of phenotypes. Inouye et al. [54] report a multivariate
analysis that utilizes the correlation structure of the 130metabolitesmea-
sured on their NMR platform. An unsupervised algorithm is used to iden-
tify metabolic networks and in the next step a multivariate test of
association for each of the networks with the SNP panel is performed.
The authors report 7 new loci using this method. These results indicate
that mGWAS analyses proﬁt from a shift from the univariate analysis
paradigm to joint modeling of phenotypes to improve the power in iden-
tiﬁcation of novel loci as well as to improve our understanding of the
biological function for known loci.
8. Towards mechanistic models
To completely understand the relations between different metabo-
lites in the various tissues and cell types, it is essential to have a full
description of all relevant metabolic reactions and the involved
enzymes and transporter proteins. This knowledge can be utilized to de-
velop mathematical models that describe the ﬂuxes through the meta-
bolic system. Furthermore, these models can then be used to predict
how ﬂuxes and metabolite levels change as a consequence of genetic
variation. This modeling approach is generally referred to as ‘bottom-
up’ systems biology [55].
Recently, in a global research effort several genome-scale metabolic
models (GSMMs) have beenmerged into a consensusmodel for human
metabolism [56]. The key difference between this model and pathway
databases is that GSMMs are represented mathematically and have
typically undergone additional curation steps that enable mathematical
analysis of these models. Most importantly, curation consists of
1) ensuring that all reactions are mass balanced, 2) ﬁlling the gaps in
the model such that the network is fully connected, and 3) checking
that the model is functionally valid, i.e. it has to faithfully predict
whichmetabolic conversions an organism (or tissue) is capable of. A de-
tailed protocol for the reconstruction and curation of organism and
tissue-speciﬁc GSMMs has recently been described by Thiele and
Palsson [57].
Given a fully functional GSMM, its behavior can be analyzed in terms
of the space of feasible steady state ﬂuxes through the network, using a
set of techniques commonly referred to as constraint-based analysis
(CBA) [58–61]. An application of CBA that is of particular interest to
metabolic research in humans is to simulate changes in the ﬂux distri-
bution in response to perturbations that reﬂect pathological or drug
treated states. Shlomi et al. [62] and Thiele et al. [56] have used this
method to predict metabolite biomarkers for inborn errors of metabo-
lism. Their approach consisted of predicting the variation in metabolite
concentrations and comparing this variation between the healthy case,
in which ﬂuxes could pass through the reaction associated with the
gene of interest, and the disease case, for which this reaction was
blocked. Applying this method on the consensus model of human
metabolism, Thiele et al. [56] were able to predict directional changes
in metabolite biomarkers with an accuracy of 77%. See Box 1 for a com-
prehensive overview of the different approaches to perform pathway
analyses of mGWAS results.
Recently, the use of human GSMMs as a scaffold for the integration
and interpretation of omics data has been pioneered by Lewis et al.
[63], Jerby and Ruppin [64], and Mardinoglu et al. [65]. However,
GSMMs have not yet been used in the analysis and interpretation
mGWAS results. The main advantage of CBA is that it goes beyondtraditional methods of pathway analysis where pathways are either
represented as pre-deﬁned gene sets or as reaction chains that follow
from graph-based searches. Therefore, its application to the mGWAS
setting has great potential for providing true mechanistic insight into
the links between genetic loci and metabolic phenotypes and consti-
tutes a promising direction for future research. Ultimately integration
of GSMMs with genetic data and expression and clinical phenotypes
will help unravel disease patho-physiology and identify optimal indi-
vidualized treatment strategies [66,67].
9. Conclusions
The ﬁrst waves of metabolomics and genetic analyses by mGWAS
have provided a wealth of insight into the genetic basis of metabolic
individuality and risk factors for common metabolic disorders, even
with modest sample sizes and conventional and conservative statistical
approaches. However, true understanding of the interrelation between
common metabolic disorders, metabolites and genetic variation
requires in depth insight into the associated pathways and their regula-
tion. One approach to gain this insight is to mine available pathway
databases using statistical tools and this approach has already proven
its value in mGWAS. The next step in pathway analyses is to include
stoichiometric and kinetic parameters and complement the statistical
analyses with a more comprehensive systems biology bases approach
using mathematical modeling. GSMMs are a ﬁrst step towards that di-
rection, but thus far lack quantitative information. Inclusion of quantita-
tive data on the regulation of enzyme activity and reaction kinetics will
be vital for developing more accurate predictive models [68]. The
combined efforts of numerous research groups around the world to
address these issues will pave the way for the application of compre-
hensive systems biology based approaches to gain insight into the ge-
netics of the human metabolome and especially its relation to disease.
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